PharmacoMicrobiomics: The Drug-Microbiome Portal

How Bugs Modulate Drugs?

Launched on 11/11/11; Current Release 1.3 (21 March 15)

Welcome To PharmacoMicrobiomics!

The PharmacoMicrobiomics web portal is a part of an initiative to explore the interactions between human-associated microbes (human microbiome) and drugs by building a knowledgebase that allows interested students and investigators "to predict the behavior of untested members of drug classes or unstudied microbial species, and to design laboratory experiments for testing these predictions. (More in BMC Bioinformatics 2011, 12(Suppl 7):A10)



What to Find Here?

You will be able to find different types of information mostly related to the effect of microbes on drugs (more specifically on the effect of human microbiota on drug disposition or pharmacokinetics). In the future, there may be more information about more complex drug-microbe interactions, and about microbes as drugs, drug factories, or drug-delivery vehicles.


You now can find several entries in the database, including:

You can also find more entries still in "draft" format (mostly Google Docs) that describe a long reading/task list for our current or future curators, and also for those community volunteers who are willing to join our efforts.


Random Interaction

Gut
Cholesterol (5997)
Eubacterium coprostanoligenes (290054)
8789734
increase excretion
Gut microbial reduction of cholesterol generates coprostanol, which cannot be reabsorbed and is excreted. This transformation effectively removes cholesterol from circulation. Coprostanol represents up to 50% of the steroids in human feces, and germ-free mice colonized with microbes from high- and low-cholesterol–reducing patients produce distinct amounts of coprostanol. It is also possible that cholesterol-reducing bacteria decrease serum cholesterol. Specifically, in Eubacterium coprostanoligenes, coprostanol synthesis may involve oxidation to 5-cholesten-3-one followed by alkene isomerization to 4-cholesten-3-one, conjugate reduction, and ketone reduction. Inhibition of cholesterol reabsorption is a clinically validated strategy for lowering cholesterol. (See record)


Credits

This drug-microbiome database was designed and built as the graduation project of the Open Source Technologies track at the Information Technology Institute (ITI) in June, 2011.

Django, the Python-based framework, was used to build the web portal, and JQuery libraries. JLinkPreview plugin is provided by Sarpdoruk Tahmaz. This template is distributed under a Creative Commons Attribution 2.5 License by Arcsin Web Templates. The project is hosted by WebFaction.